UC Berkeley, Samoa to Share Benefit from AIDS Drug

Courtesy of Paul Alan Cox and Patricia StewartThe Samoan mamala tree, Homalanthus nutans, from which the promising anti-AIDS drug Prostratin was isolated.The University of California, Berkeley, and the tiny, two-island Pacific Ocean nation of Samoa will share equally in royalties from an anti-AIDS drug called prostratin, in an agreement that could be a model for the development and commercialization of drugs resulting from ethnobotany efforts. Prostratin is extracted from the bark of the mamala

Written byHarvey Black
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

Courtesy of Paul Alan Cox and Patricia Stewart

The Samoan mamala tree, Homalanthus nutans, from which the promising anti-AIDS drug Prostratin was isolated.

The University of California, Berkeley, and the tiny, two-island Pacific Ocean nation of Samoa will share equally in royalties from an anti-AIDS drug called prostratin, in an agreement that could be a model for the development and commercialization of drugs resulting from ethnobotany efforts. Prostratin is extracted from the bark of the mamala tree and has long been used as a hepatitis treatment by native healers in Samoa, a nation inhabited by fewer than 200,000 people. Prostratin works by forcing the AIDS virus out of reservoirs in the body, which increases the efficacy of antiretroviral drugs. Jay Keasling will be leading efforts to isolate and clone the genes for prostratin. If a genetically engineered version of the drug is produced, the university and Samoa will share the ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Related Topics

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies